Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients

Suleyman Karti
June 2009
Endocrine (1355008X);Jun2009, Vol. 35 Issue 3, p380
Academic Journal
Abstract  Type 2 diabetes mellitus is the leading cause of macrovascular diseases and related death. Additionally, diabetes mellitus is frequently complicated by other cardiovascular risk factors, such as hypercholesterolemia, hypertension, obesity, hypercoagulability, and inflammation. We wanted to evaluate and compare the effects of treating with a one-year course of atorvastatin or simvastatin on inflammatory markers such as high sensitive C-reactive protein (hsCRP), fibrinogen, and ferritin in uncontrolled type 2 diabetic patients. Also, we planned to investigate the correlation between inflammatory markers and metabolic parameters. Fifty type 2 diabetic patients (30 women, 20 men; mean age: 49.9 ± 8.5 years) were enrolled into the study. Twenty healthy subjects, matched on body mass index and age, were also included in the study as a control group. Diabetic patients were divided into two groups and received simvastatin or atorvastatin (Group S and A, respectively). After 1 year of statin treatment (Group A), there were significant decreases in total cholesterol (217.3 ± 46.5–173.8 ± 37.2 mg/dl; P P P P P P P P P P r = 0.42; P = 0.005, with ∆hsCRP), (r = 0.40; P = 0.008, with ∆fibrinogen), (r = 0.46; P = 0.002, with ∆ferritin) and ∆HDL (r = −0.50; P r = −0.32; p = 0.042, with ∆fibrinogen), (r = −0.48; P 


Related Articles

  • Study of C Reactive Protein in Type 2 Diabetes and its Relation with Various Complications from Eastern India. Bandyopadhyay, Ramtanu; Paul, Rudrajit; Basu, Asish K.; Chakraborty, ParthaPratim; Mitra, Sudipan // Journal of Applied Pharmaceutical Science;Jul2013, Vol. 3 Issue 7, p156 

    Diabetes is associated with a pro-inflammatory state and endothelial dysfunction. Various markers of inflammation like C Reactive Protein (CRP) are elevated significantly in diabetic population. The levels of these markers also correlate with the severity of diabetes and presence of various...

  • C-reactive protein further reduced with TZDs.  // Endocrine Today;Feb2010, Vol. 8 Issue 2, p20 

    The article discusses research on the clinical use of C-reactive protein in patients with type 2 diabetes, by S. E. Kahn and colleagues, published in the 2010 issue of "Diabetes Care."

  • Exenatide Improved Markers of Hepatic Function Over 3 Years in Patients With Type 2 Diabetes. Nielsen, Loretta; Xuesong Guan; Bowlus, Christopher; Holcombe, John; Maggs, David; Wintle, Matthew // Diabetes;Jun2007 Supplement 1, Vol. 56, pA149 

    Type 2 diabetes (T2D), obesity, and nonalcoholic fatty liver disease (NAFLD) are emerging public health concerns that often co-exist, with diabetes and obesity the two most important risk factors for NAFLD. Because exenatide is associated with improvement in glycemic control and weight...

  • CONFERENCE ROUND-UP.  // Pulse;9/29/2010, Vol. 70 Issue 28, p9 

    The article offers world news briefs related to medical research in 2010 including a survey which reveals the poor provision of pulmonary rehabilitation in Great Britain, the intensive control of blood glucose for patients with type 1 diabetes and significant improvements in glycaemic control...

  • Diabetes can be managed more effectively.  // Clinical Advisor;Apr2011, Vol. 14 Issue 4, p16 

    The article offers information on the proper management of diabetes. It is states that three strategies should be done to improve diabetes management including a standardized care of diabetic patients, offering incentives to providers and patients, and making technological innovations in...

  • Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. Yilmaz, Hamiyet; Gursoy, Alptekin; Sahin, Mustafa; Demirag, Nilgun Guvener // Acta Diabetologica;Dec2007, Vol. 44 Issue 4, p187 

    The aim of this study was to compare the efficacy of treatment with insulin alone, insulin plus acarbose, insulin plus metformin, or insulin plus rosiglitazone in type 2 diabetic subjects who were previously on insulin monotherapy, and to evaluate the effects of these treatments on...

  • Cyclophilin-A: a potential screening marker for vascular disease in type-2 diabetes.  // Canadian Journal of Physiology & Pharmacology;Aug2012, Vol. 90 Issue 8, p1005 

    The pathophysiology of vascular disease in diabetes involves abnormalities in endothelial cells, vascular smooth muscle cells, and monocytes. The metabolic abnormalities that characterize diabetes, such as hyperglycemia, increased free fatty acids, and insulin resistance, each provoke molecular...

  • The antidiabetic gutsy role of metformin uncovered? Burcelin, Rémy // Gut;May2014, Vol. 63 Issue 5, p706 

    The author comments on the research study concerning on the medical role of metformin as treatment for lowering hyperglycaemia in type 2 diabetic patients. He mentions the antidiabetic effect of metformin abrogated by an antibiotic treatment reinforcing the significant of gut microbiota. He also...

  • EFFECTS OF ROYAL JELLY SUPPLEMENTATION ON LIPID PROFILE AND HIGH-SENSITIVITY C-REACTIVE PROTEIN LEVELS IN TYPE-2 DIABETIC WOMEN: A PILOT STUDY. Mobasseri, Majid; Pourmoradian, Samira; Mahdavi, Reza; Faramarzi, Elnaz // Current Topics in Nutraceutical Research;Aug2014, Vol. 12 Issue 3, p101 

    The aims of this study were to determine the effect of royal jelly supplementation as a complementary therapy on lipid profile and hs-CRP levels in type 2 diabetic females. In this pilot randomized clinical trial, fifty female volunteers with type2 diabetes were assigned into the supplemented...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics